BioCentury | Jun 15, 2009
Company News

Adeona, Hartlab LLC deal

...company Adeona will acquire Hartlab, a CLIA-certified clinical lab, for $280,000 in cash. Adeona (formerly Pipex Pharmaceuticals Inc....
BioCentury | Sep 29, 2008
Product Development

Dry AMD pipeline

...Othera OT-551 Ophthalmic solution of a small molecule catalytic antioxidant derived from Tempol-H Ph II Pipex...
BioCentury | Sep 29, 2008
Product Development

Ophthalmic deals

...AMD and diabetic macular edema (DME). MacuSight retains rights elsewhere. May 08 Pipex (AMEX:PP) Undisclosed Pipex...
...that includes E10030, a preclinical compound to treat wet AMD Jul 07 Pipex (AMEX:PP) Undisclosed Pipex...
BioCentury | Aug 25, 2008
Company News

Pipex, University of California deal

...license from the university to develop and commercialize oral dnaJP1 (formerly AT-001) for autoimmune diseases. Pipex...
...university will receive an undisclosed upfront payment and is eligible for undisclosed milestones, plus royalties. Pipex’s...
...III testing to treat women with relapsing-remitting multiple sclerosis (MS) (see BioCentury, Nov. 7, 2005). Pipex Pharmaceuticals Inc....
BioCentury | Jul 14, 2008
Company News

Pipex board of directors update

Pipex Pharmaceuticals Inc. (AMEX:PP), Ann Arbor, Mich. Business: Neurology, Pulmonary, Autoimmune Resigned: Daniel Dorman WIR Staff autoimmune Neurology Pulmonary...
BioCentury | Jul 14, 2008
Finance

Ebb & Flow

...was up DKK26.5 (12%) to DKK247.5 on the week (see “NeuroSearch TIPOs the Scales,” A14). Pipex...
...acuity vs. placebo in a Phase II trial to treat dry age-related macular degeneration (AMD). Pipex...
BioCentury | Jul 14, 2008
Clinical News

Zinthionein zinc-monocysteine: Phase II data

...seconds for Zinthionein vs. increases of 0.19 and 0.54 for placebo. Zinthionein was well tolerated. Pipex Pharmaceuticals Inc....
BioCentury | Jul 14, 2008
Company News

Pipex management update

Pipex Pharmaceuticals Inc. (AMEX:PP), Ann Arbor, Mich. Departed: Charles Bisgaier as president Transitioned: Nicholas Stergis to CEO while remaining vice chairman; he replaces Steve Kanzer, who remains chairman WIR Staff...
BioCentury | Jul 9, 2008
Clinical News

Pipex's Zinthionein meets dry AMD endpoint

...double-blind study of the covalently linked form of zinc-monocysteine complex enrolled 80 patients. On Wednesday, Pipex...
BioCentury | Jun 2, 2008
Company News

Pipex deal

...holds the patents to use flupirtine for the respective indications. Financial terms were not disclosed. Pipex...
...receptor antagonist and potassium (K) channel modulator marketed since 1981 in Europe to treat pain. Pipex Pharmaceuticals Inc....
Items per page:
1 - 10 of 43
BioCentury | Jun 15, 2009
Company News

Adeona, Hartlab LLC deal

...company Adeona will acquire Hartlab, a CLIA-certified clinical lab, for $280,000 in cash. Adeona (formerly Pipex Pharmaceuticals Inc....
BioCentury | Sep 29, 2008
Product Development

Dry AMD pipeline

...Othera OT-551 Ophthalmic solution of a small molecule catalytic antioxidant derived from Tempol-H Ph II Pipex...
BioCentury | Sep 29, 2008
Product Development

Ophthalmic deals

...AMD and diabetic macular edema (DME). MacuSight retains rights elsewhere. May 08 Pipex (AMEX:PP) Undisclosed Pipex...
...that includes E10030, a preclinical compound to treat wet AMD Jul 07 Pipex (AMEX:PP) Undisclosed Pipex...
BioCentury | Aug 25, 2008
Company News

Pipex, University of California deal

...license from the university to develop and commercialize oral dnaJP1 (formerly AT-001) for autoimmune diseases. Pipex...
...university will receive an undisclosed upfront payment and is eligible for undisclosed milestones, plus royalties. Pipex’s...
...III testing to treat women with relapsing-remitting multiple sclerosis (MS) (see BioCentury, Nov. 7, 2005). Pipex Pharmaceuticals Inc....
BioCentury | Jul 14, 2008
Company News

Pipex board of directors update

Pipex Pharmaceuticals Inc. (AMEX:PP), Ann Arbor, Mich. Business: Neurology, Pulmonary, Autoimmune Resigned: Daniel Dorman WIR Staff autoimmune Neurology Pulmonary...
BioCentury | Jul 14, 2008
Finance

Ebb & Flow

...was up DKK26.5 (12%) to DKK247.5 on the week (see “NeuroSearch TIPOs the Scales,” A14). Pipex...
...acuity vs. placebo in a Phase II trial to treat dry age-related macular degeneration (AMD). Pipex...
BioCentury | Jul 14, 2008
Clinical News

Zinthionein zinc-monocysteine: Phase II data

...seconds for Zinthionein vs. increases of 0.19 and 0.54 for placebo. Zinthionein was well tolerated. Pipex Pharmaceuticals Inc....
BioCentury | Jul 14, 2008
Company News

Pipex management update

Pipex Pharmaceuticals Inc. (AMEX:PP), Ann Arbor, Mich. Departed: Charles Bisgaier as president Transitioned: Nicholas Stergis to CEO while remaining vice chairman; he replaces Steve Kanzer, who remains chairman WIR Staff...
BioCentury | Jul 9, 2008
Clinical News

Pipex's Zinthionein meets dry AMD endpoint

...double-blind study of the covalently linked form of zinc-monocysteine complex enrolled 80 patients. On Wednesday, Pipex...
BioCentury | Jun 2, 2008
Company News

Pipex deal

...holds the patents to use flupirtine for the respective indications. Financial terms were not disclosed. Pipex...
...receptor antagonist and potassium (K) channel modulator marketed since 1981 in Europe to treat pain. Pipex Pharmaceuticals Inc....
Items per page:
1 - 10 of 43